WO2024257026 - VIRUS-LIKE PARTICLES FOR THE TREATMENT OF SARS-COV2
National phase entry is expected:
Publication Number
WO/2024/257026
Publication Date
19.12.2024
International Application No.
PCT/IB2024/055822
International Filing Date
14.06.2024
Title **
[English]
VIRUS-LIKE PARTICLES FOR THE TREATMENT OF SARS-COV2
[French]
PARTICULES DE TYPE VIRUS POUR LE TRAITEMENT DU SARS-COV2
Applicants **
SEQIRUS INC.
475 Green Oaks Parkway
Holly Springs, North Carolina 27540, US
Inventors
CAI, Yongfei
c/o Seqirus Inc.
475 Green Oaks Parkway
Holly Springs, North Carolina 27540, US
Priority Data
63/508,537
16.06.2023
US
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| * | |
International Searching Authority |
USPTO
* |
| * | |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Translation |
|
Recalculate
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing | 2235 | |
| EPO | Filing, Examination | 18508 | |
| Japan | Filing | 532 | |
| South Korea | Filing | 575 | |
| USA | Filing, Examination | 16005 |
Total: 37855 USD
Abstract[English]
The present disclosure relates to a virus-like particle (VLP) comprising one or more antigens for use as a vaccine. The present disclosure further relates to uses of the vaccine for the treatment of a SARS-CoV-2 infection or coronavirus disease 2019 (COVID-19).[French]
La présente invention concerne une particule de type virus (VLP) comprenant un ou plusieurs antigènes destinés à être utilisés en tant que vaccin. La présente invention concerne en outre des utilisations du vaccin pour le traitement d'une infection par le SARS-CoV-2 ou d'une maladie à coronavirus 2019 (COVID-19).